Normal vehicle
Used at 15–20% as a suspended or partly dissolved acid. High free-acid load contacts the skin all at once.
Problem: Burning, stinging and itching are the most common reasons patients stop azelaic acid.
Delivery comparator
Standard moisturisers and serums work, but their actives sit on the surface, oxidise and arrive all at once. Entrapping the same molecules in Cetosome® nanovesicles changes where they go, how long they last and how the skin tolerates them.
01 Moisturisers
A normal moisturiser hydrates by drawing water into the surface and slowing evaporation, and most of its actives stay in the film until wiped or washed away. A Cetosome® moisturiser adds lamellar lipids that resemble the barrier and holds actives in vesicles that release gradually, so benefits outlast the film. Barrier support improves.
| Normal moisturiser | Cetosome® moisturiser | |
|---|---|---|
| Where it acts | Surface film; humectants draw water, occlusives slow loss | Surface film plus lamellar lipid structure that integrates with barrier lipids |
| Active payload | Mostly unprotected; oxidises and rubs off | Held in vesicles; shielded from air and light |
| Duration | Peaks at application, fades over hours | Gradual release over up to 24 h |
| Barrier fit | Depends on lipid ratios; often non-lamellar | Cetylated lamellae resemble ceramide–cholesterol–fatty-acid mortar |
| Best for | Simple hydration | Barrier repair with actives (ceramides, niacinamide, urea) |
Barrier lipid architecture [3]; molecular size limits for ceramides[2]; vesicle stability and release [4].
02 Serums
A normal serum dissolves actives in water, alcohol or glycols and releases them at once. That gives the early concentration peak linked to stinging, redness and dryness, followed by a fast decline. A Cetosome® serum keeps most of the active in vesicles and releases it over hours, lowering the peak while holding effective levels longer.
| Normal serum | Cetosome® serum | |
|---|---|---|
| Free-active peak | High in the first minutes to an hour | Lower; spread over hours |
| Stinging / erythema risk | Tracks the peak; highest in weeks 1–4 | Reduced by lower peak and no harsh solvents |
| Solvent system | Often ethanol, propylene glycol or high acid | Water-rich; ethanol- and PG-free systems demonstrated |
| Multiple actives | One solubility class per serum | Hydrophilic + lipophilic in one vehicle |
| Shelf behaviour | Active degrades in solution | Vesicle stability 18–26 months reported |
Retinoid irritation patterns [7][8]; vehicle tolerability data for a cetosomal versus alcohol-based solution [9].
03 Molecule toggle
Each molecule gains something different from entrapment. Hydrophilic actives such as tranexamic acid and niacinamide gain a lipid-compatible carrier. Lipophilic retinoids and ceramides gain oxidation protection and a barrier-like matrix. Irritating acids gain a lower free fraction. Follicular actives gain a solvent-free vehicle. Select a molecule to see the trade-offs.
Normal vehicle
Used at 15–20% as a suspended or partly dissolved acid. High free-acid load contacts the skin all at once.
Problem: Burning, stinging and itching are the most common reasons patients stop azelaic acid.
Cetosome®-entrapped
Partitioned into the vesicle and released as the particles disassemble in the stratum corneum, so less free acid sits on nerve-rich skin at any one moment.[5][6]
Honest limitation: Encapsulation changes tolerability and residence time, not the drug's mechanism. Efficacy endpoints for encapsulated azelaic acid still need head-to-head trials.
Normal vehicle
A highly water-soluble zwitterion in a serum. It penetrates poorly through the lipid-rich stratum corneum.
Problem: Low partitioning into barrier lipids means much of the dose stays on the surface.
Cetosome®-entrapped
Carried in the polar mantle and solvent domains of the vesicle, which gives a water-loving molecule a lipid-compatible carrier.[2][4]
Honest limitation: Topical tranexamic acid evidence is still developing. Delivery gains do not replace a clinician's choice of pigmentation regimen.
Normal vehicle
Waxy, poorly soluble lipids that crystallise out of simple bases unless carefully co-formulated with cholesterol and fatty acids.
Problem: Above the ~500 Da threshold, so they act mostly as a surface film.
Cetosome®-entrapped
Housed in a lamellar structure that resembles the barrier's own ceramide–cholesterol–fatty-acid arrangement, supporting even distribution across the surface.[3][2]
Honest limitation: Ceramides mainly work where the barrier is. Deep delivery is neither needed nor claimed.
Normal vehicle
Retinol and retinaldehyde oxidise on light and air exposure. Prescription retinoids are applied as concentrated films.
Problem: Retinoid dermatitis (dryness, peeling, erythema) is the main barrier to adherence, especially in the first weeks.
Cetosome®-entrapped
The lipid shell shields the molecule from oxidation, and gradual release flattens the early-hours concentration peak linked to irritation.[7][8]
Honest limitation: Expect better tolerability and stability, not a stronger retinoid. Sun protection and slow titration are still needed.
Normal vehicle
Small, very water-soluble molecules at low pH (AHAs) or high concentration (urea). They penetrate readily, and the acidity is the irritant.
Problem: Low pH and a high free-acid fraction cause immediate stinging on sensitive or broken skin.
Cetosome®-entrapped
Holding part of the acid load in the aqueous core moderates the free fraction at the surface. The vesicles stay stable across pH 4–10.[4]
Honest limitation: Exfoliating acids are meant to act superficially. The goal of encapsulating them is gentleness, not depth.
Normal vehicle
Stable and well tolerated at 2–5%. At high concentrations (10%+) some users get flushing or stinging.
Problem: Escalating concentration to compensate for delivery raises irritation.
Cetosome®-entrapped
Better partitioning lets a moderate concentration do the work of a higher one, and controlled release spreads exposure over the day.[2]
Honest limitation: Niacinamide is already one of the best-tolerated actives. The gain is incremental.
Normal vehicle
Conventional minoxidil solutions rely on ethanol and propylene glycol for solubility, both common causes of scalp itching and flaking.
Problem: Solvent-related scalp irritation is a leading reason for stopping treatment.
Cetosome®-entrapped
The cetosomal minoxidil described in the literature is ethanol- and propylene-glycol-free. In a randomised comparison, 9% of patients on it reported adverse events versus 41% on alcohol-based minoxidil (p = 0.02).[9][10]
Honest limitation: The evidence comes from small, industry-affiliated trials: 40 of 80 completed, open-label, plus one retrospective study. Efficacy differences were not statistically significant.
04 Test your current routine
Paste the full ingredient list from your current product. The decoder finds tracked actives, flags vehicle stressors such as denatured alcohol, propylene glycol and fragrance allergens, and checks for declared delivery systems. It then explains which actives would most benefit from nanovesicle entrapment. It runs entirely in your browser and stores nothing.
Runs entirely in your browser. Nothing is sent or stored. This is an educational reading of the vehicle, not a medical assessment.
Actives detected
Vehicle stressors
Delivery system signals
Prefer your actives in a Cetosome® vehicle?
05 Honest clinical limitations
Encapsulation changes delivery, not pharmacology. It cannot make a weak active strong, replace sun protection, or treat disease that needs a prescription. The best controlled data for Cetosome® vehicles come from small, industry-affiliated minoxidil studies, so tolerability benefits for other actives are mechanistically grounded but not yet quantified in randomised trials.
Want to try a Cetosome® vehicle? These formulations are dispensed through dermatology rather than mass retail. In India, the Monoskin range is the direct route: ask your dermatologist, or start here.
A normal moisturiser hydrates and occludes the surface well. A Cetosome® moisturiser adds lamellar, barrier-like lipid structure and holds actives such as ceramides or niacinamide in vesicles that release gradually, so the benefit lasts longer and is more evenly distributed. For a basic emollient-only product, the difference is smaller.
For irritating or unstable actives such as retinoids, acids and azelaic acid, encapsulation mainly improves stability and tolerability by lowering the early concentration spike. For very gentle actives the gains are incremental. Encapsulation changes delivery, not the pharmacology of the molecule.
Not reliably. Cetyl and cetearyl alcohol are common thickeners in most creams and do not indicate Cetosomes®. Look for an explicit delivery-system claim and ask for particle size, zeta potential and stability data.
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.